Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 3, 2011, Pages

  Li, Hua ^a   Martin, Aline ^a   David, Valentin ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Fibroblast growth factor 23; Fibroblast growth factor receptor 3; Fibroblast growth factor receptor 4; Hypophosphatemia; Klotho; Vitamin D

Indexed keywords

COTRANSPORTER; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEEDBACK SYSTEM; FEMALE; GENE DELETION; GENE EXPRESSION; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY; KNOCKOUT MOUSE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN D METABOLISM; WILD TYPE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; GENE DELETION; HOMOZYGOTE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; PHENOTYPE; PHOSPHATES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 79952161016     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00499.2010     Document Type: Article

References (52)

1. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004. (Pubitemid 39551149)
2. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007. (Pubitemid 350224109)
3. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981, 2001. (Pubitemid 32924744)
4. Brownstein CA, Zhang J, Stillman A, Ellis B, Troiano N, Adams DJ, Gundberg CM, Lifton RP, Carpenter TO. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology 151: 492-501, 2010.
5. Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF. Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int 60: 147-155, 2001. (Pubitemid 32587549)
6. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12: 390-397, 1996. (Pubitemid 26105928)
7. Cunningham J, Gomes H, Seino Y, Chase LR. Abnormal 24-hydroxylation of 25-hydroxyvitamin D in the X-linked hypophosphatemic mouse. Endocrinology 112: 633-638, 1983.
8. Farrow EG, Davis SI, Summers LJ, White KE. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20: 955-960, 2009.
9. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005. (Pubitemid 40464013)
10. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297: F282-F291, 2009.
11. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Shawkat Razzaque M, Rosenblatt KP, Baum MG, Kuro OM, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24: 3438-3450, 2010.
12. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117: 2684-2691, 2007. (Pubitemid 47494368)
13. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y. α-Klotho as a regulator of calcium homeostasis. Science 316: 1615-1618, 2007.
14. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997. (Pubitemid 27494749)
15. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro OM. Tissue-specific expression of β-klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695, 2007. (Pubitemid 47501965)
16. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006. (Pubitemid 43847540)
17. 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2004.
18. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29: 91-99, 2004. (Pubitemid 40260033)
19. Liu S, Guo R, Tu Q, Quarles LD. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277: 3686-3697, 2002. (Pubitemid 34953243)
20. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1647, 2007. (Pubitemid 46870300)
21. Liu S, Tang W, Fang J, Ren J, Li H, Xiao Z, Quarles LD. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol 23: 1505-1518, 2009.
22. Liu S, Tang W, Vierthaler L, Quarles L. Evidence for a distal-toproximal tubule feedback (Abstract). J Am Soc Nephrol. In press.
23. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006. (Pubitemid 43673410)
24. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19: 2342-2350, 2008.
25. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006. (Pubitemid 44035308)
26. Marsell R, Krajisnik T, Goransson H, Ohlsson C, Ljunggren O, Larsson TE, Jonsson KB. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 23: 827-833, 2008. (Pubitemid 351767553)
27. Martin A, David V, Vico L, Thomas T. Impaired energetic metabolism consecutive to central leptin signaling leads to massive appendicular bone loss in hindlimb suspended rats. J Bone Miner Res 23: 2040-2047, 2008.
28. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 23: 433-441, 2009.
29. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006. (Pubitemid 44871378)
30. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1α-hydroxylase. Kidney Int 75: 1166-1172, 2009.
31. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005. (Pubitemid 41653049)
32. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118: 3820-3828, 2008.
33. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112: 642-646, 2003. (Pubitemid 38057701)
34. Roy S, Tenenhouse HS. Transcriptional regulation and renal localization of 1,25-dihydroxyvitamin D3-24-hydroxylase gene expression: effects of the Hyp mutation and 1,25-dihydroxyvitamin D3. Endocrinology 137: 2938-2946, 1996.
35. +-dependent phosphate co-transport activity and 1α,25- dihydroxyvitamin D3 production. J Biol Chem 278: 2206-2211, 2003.
36. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005. (Pubitemid 40189356)
37. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150: 4835-4845, 2009.
38. Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Imura A, Nabeshima Y, Miyamoto K. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292: F769-F779, 2007. (Pubitemid 46220545)
39. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004. (Pubitemid 38787398)
40. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001. (Pubitemid 32488266)
41. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005. (Pubitemid 41447065)
42. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004. (Pubitemid 39576657)
43. Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, Meitinger T. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 6: 165-171, 1997. (Pubitemid 27078072)
44. Tomoe Y, Segawa H, Shiozawa K, Kaneko I, Tominaga R, Hanabusa E, Aranami F, Furutani J, Kuwahara S, Tatsumi S, Matsumoto M, Ito M, Miyamoto K. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice. Am J Physiol Renal Physiol 298: F1341-F1350, 2010.
45. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003. (Pubitemid 37542205)
46. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006. (Pubitemid 44949607)
47. Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125: 3615-3623, 1998. (Pubitemid 28469962)
48. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5: 110-116, 2010.
49. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol Endocrinol Metab 275: E700-E708, 1998.
50. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277: 28265-28270, 2002. (Pubitemid 34966781)
51. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656, 2005. (Pubitemid 41446602)
52. Yuan B, Xing Y, Horst RL, Drezner MK. Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1α-hydroxylase activity in the hyp-mouse. Endocrinology 145: 3804-3812, 2004. (Pubitemid 39037568)